New hope for tough pancreatic cancer: combo therapy with or without radiation

NCT ID NCT06662006

Recruiting now Disease control Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for people with advanced pancreatic cancer that has spread and is no longer helped by first-line chemotherapy. It tests a mix of drugs (nal-IRI, 5-FU, leucovorin, benmelstobart, and anlotinib) with or without focused radiation (SBRT). The goal is to see if this combination can shrink or control tumors. About 56 participants will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED METASTATIC PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma malignant pancreatic neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED METASTATIC PANCREATIC CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
RECRUITING

Nanjing, Jiangsu, 025, China

Contact Phone: •••-•••-•••• Email: •••••@•••••